MorphoSys AG (MOR) PT Set at €55.00 by Goldman Sachs Group, Inc. (The)
MorphoSys AG (ETR:MOR) has been given a €55.00 ($65.48) price objective by equities research analysts at Goldman Sachs Group, Inc. (The) in a report issued on Thursday. The firm currently has a “neutral” rating on the stock.
A number of other brokerages have also recently issued reports on MOR. Berenberg Bank set a €68.00 ($80.95) target price on MorphoSys AG and gave the stock a “buy” rating in a report on Thursday, May 25th. Independent Research GmbH set a €77.00 ($91.67) target price on MorphoSys AG and gave the stock a “buy” rating in a report on Monday, August 7th. Commerzbank Ag set a €76.00 ($90.48) target price on MorphoSys AG and gave the stock a “buy” rating in a report on Tuesday, June 6th. Finally, HSBC Holdings plc set a €59.00 ($70.24) target price on MorphoSys AG and gave the stock a “neutral” rating in a report on Friday, July 14th. Three research analysts have rated the stock with a hold rating and four have given a buy rating to the stock. The stock currently has a consensus rating of “Buy” and an average target price of €69.57 ($82.82).
Shares of MorphoSys AG (ETR MOR) opened at 63.227 on Thursday. MorphoSys AG has a 12-month low of €35.72 and a 12-month high of €70.90. The firm’s 50-day moving average price is €60.18 and its 200 day moving average price is €58.94. The firm’s market cap is €1.83 billion.
TRADEMARK VIOLATION NOTICE: This news story was published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this news story on another domain, it was copied illegally and republished in violation of US & international copyright and trademark legislation. The legal version of this news story can be accessed at https://www.thecerbatgem.com/2017/09/07/morphosys-ag-mor-pt-set-at-55-00-by-goldman-sachs-group-inc-the.html.
About MorphoSys AG
MorphoSys AG, together with its subsidiaries, engages in the research, development, and optimization of therapeutic antibody drug candidates in partnerships with pharmaceutical and biotechnology companies. The company, together with its pharmaceutical partners, develops a therapeutic pipeline of approximately 100 human antibody drug candidates for the treatment of cancer, rheumatoid arthritis, Alzheimer's disease, infectious diseases, cardiovascular dysfunction, and inflammation.
Receive News & Stock Ratings for MorphoSys AG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MorphoSys AG and related stocks with our FREE daily email newsletter.